Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ELTX

Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Elicio Therapeutics logo

About Elicio Therapeutics Stock (NASDAQ:ELTX)

Advanced Chart

Key Stats

Today's Range
$9.20
$9.99
50-Day Range
N/A
52-Week Range
N/A
Volume
21,884 shs
Average Volume
37,983 shs
Market Capitalization
$159.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

Elicio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

ELTX MarketRank™: 

Elicio Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 700th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elicio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elicio Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Elicio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Elicio Therapeutics are expected to grow in the coming year, from ($3.89) to ($3.62) per share.

  • Percentage of Shares Shorted

    6.17% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 9.4.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 18.56%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Elicio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Elicio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.17% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 9.4.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently increased by 18.56%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      50.90% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 35.03% of the stock of Elicio Therapeutics is held by institutions.

    • Read more about Elicio Therapeutics' insider trading history.
    Receive ELTX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    ELTX Stock News Headlines

    Digital Dollar Alert: Protect Your Wealth Before It’s Too Late
    134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts warn a programmable dollar could erase your privacy and control your spending. A free guide reveals how to protect your savings before the system goes live.
    Elicio Therapeutics Secures $10 Million in Financing
    Elicio Therapeutics: Q1 Earnings Snapshot
    See More Headlines

    ELTX Stock Analysis - Frequently Asked Questions

    Elicio Therapeutics, Inc. (NASDAQ:ELTX) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.20.

    Elicio Therapeutics (ELTX) raised $40 million in an initial public offering (IPO) on the week of July 26th 2021. The company issued 3,100,000 shares at $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Atreca (BCEL), Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA).

    Company Calendar

    Last Earnings
    5/13/2025
    Today
    8/03/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:ELTX
    CIK
    1555192
    Fax
    N/A
    Employees
    N/A
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $13.00
    Low Price Target
    $13.00
    Potential Upside/Downside
    +30.3%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($6.95)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$51.90 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    -185.70%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    1.83
    Quick Ratio
    1.83

    Sales & Book Value

    Annual Sales
    $2.30 million
    Price / Sales
    69.43
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($1.03) per share
    Price / Book
    -9.69

    Miscellaneous

    Outstanding Shares
    16,000,000
    Free Float
    7,855,000
    Market Cap
    $159.68 million
    Optionable
    Not Optionable
    Beta
    1.18
    Elon Musk's Next Move Cover

    Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

    Get This Free Report

    This page (NASDAQ:ELTX) was last updated on 8/3/2025 by MarketBeat.com Staff
    From Our Partners